Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01898403 · ClinicalTrials.gov registry record · NA
Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT01898403: Completed NA study, sponsored by Stanford University.
NCT01898403 is a NA study that has completed, run by Stanford University. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01898403, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
This clinical trial compares and contrasts lymph node mapping using indocyanine green (IC-GREEN), isosulfan blue (ISB), and TSC and Lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC). Study participants with malignant melanoma will undergo all 3 evaluations to assess the extent of the spread of the melanoma.
Interventions
- DRUG Indocyanine green solution
- DRUG Isosulfan blue (ISB)
- DIAGNOSTIC_TEST Lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2013-06 |
| Est. Completion | 2015-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01898403
The ClinicalTrials.gov registry entry for NCT01898403 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Indocyanine green solution is the first listed.
NCT01898403 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01898403 about?
NCT01898403 is a clinical study titled "Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma". This clinical trial compares and contrasts lymph node mapping using indocyanine green (IC-GREEN), isosulfan blue (ISB), and TSC and Lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC). Study participants with malignant melanoma will undergo all 3 evaluations to assess the extent of th...
What is the current status of trial NCT01898403?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2013-06. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01898403?
The interventions under investigation include: Indocyanine green solution (DRUG), Isosulfan blue (ISB) (DRUG), Lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT01898403?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.